MedTrace Logo

Registry Study for Talimogene Laherparepvec

NCT02173171 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2021-09-30

No results posted yet for this study

Summary

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

Conditions

  • Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial

Interventions

OTHER

Information collection

Q3M Information collection

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-27
Primary Completion
2021-09-23
Completion
2021-09-23

Countries

  • United States
  • Austria
  • Canada
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02173171 on ClinicalTrials.gov